Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364678 | PMC |
| http://dx.doi.org/10.1016/j.jinf.2021.08.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Respiratory Virus Prevalence Across Pre-, During-, and Post-SARS-CoV-2 Pandemic Periods.
Viruses
July 2025
Unit of Clinical Microbiology, Department of Health Sciences, "Magna Græcia" University, A.O.U. "R. Dulbecco", 88100 Catanzaro, Italy.
The COVID-19 pandemic significantly impacted the circulation, seasonality, and disease burden of viral respiratory infections. This study aimed to evaluate the impact of SARS-CoV-2 on the frequency of viral respiratory infections at a teaching hospital in Southern Italy by comparing data from before, during, and after the COVID-19 pandemic and by investigating how the emergence of SARS-CoV-2 affected the circulation and seasonality of other respiratory viruses. This retrospective and prospective study was performed on de-identified nasopharyngeal specimens classified as pre-COVID-19 (before 15 March 2020), during-COVID-19 (from 16 March 2020 to 5 May 2023), and post-COVID-19 (from 6 May 2023 to 31 December 2024).
View Article and Find Full Text PDFSARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine.
J Neuroimmunol
October 2025
Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, USA; Harvard Medical School, Boston, MA, USA. Electronic address:
Background: There is limited knowledge about SARS-CoV-2 spike antibody and long-term T cell responses in multiple sclerosis (MS) patients on high efficacy treatments post SARS-CoV-2 vaccine.
Objectives: To assess spike antibody and T cell responses in MS patients on fingolimod (FIN), ocrelizumab (OCR) and healthy controls (HC) post vaccine.
Methods: We studied spike antibody seroconversion rates and T cell responses by flow cytometry in HC and MS patients.
Elevated risk of new-onset chronic fatigue syndrome/myalgic encephalomyelitis up to four years after SARS-CoV-2 infection.
J Transl Med
July 2025
Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
Background: Fatigue is a common sequela of SARS-CoV-2 infection, with many COVID-19 patients subsequently developing chronic fatigue syndrome and myalgic encephalomyelitis (CFS/ME). Long-term associations between COVID-19, new-onset CFS/ME, and other independent predictors such as vaccination for SARS-CoV-2, re-infection, and blood biomarkers at time of infection remain unclear. This study investigated the incidence and independent predictors of developing new-onset CFS/ME up to 4 years post SARS-CoV-2 infection in comparison to COVID- controls.
View Article and Find Full Text PDFSpike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses.
Cell Rep
July 2025
Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK. Electronic address:
COVID-19 vaccines proved vital in controlling the SARS-CoV-2 pandemic. Both neutralizing and effector-function activities of Spike-specific antibodies are important for their protective activity. Several studies have reported that COVID-19 mRNA vaccines can lead to elevated levels of Spike-specific immunoglobulin G4 (IgG4), an anti-inflammatory subclass with reduced binding to Fcγ receptors.
View Article and Find Full Text PDFLack of Treatment Efficacy and Duration of OnabotulinumtoxinA and AbobotulinumtoxinA Post Sars-COV-2 Infection and COVID Vaccination.
Plast Aesthet Nurs (Phila)
July 2025
Ali McCoy Stengel, BSN, RN, LE, is the founder/owner of Always Beautiful Medspa, Institute, and CoolClinic, in Aurora, CO. Ali is a national Allergan trainer who has administered 700,000 Botox units and is ranked Top 5 in Botox retention.
This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study.
View Article and Find Full Text PDF